Evidence map›Paper›PMID 38761384›Full record

ArticleThe oncologist2024

Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.

Emily Connell, Émilie Gerard, Bénédicte Oules, Florence Brunet-Possenti, Anouck Lamoureux, Hugo Bonnefille, Sorilla Mary-Prey, Ana Carrasquilla, Stéphane Mouret, Nora Kramkimel and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Emily ConnellDermatology and Skin Cancer Department, Aix Marseille University, APHM, CRCM Inserm U1068, CNRS U7258, Marseille, France.
Émilie GerardDermatology Department, CHU de Bordeaux, Bordeaux, France.
Bénédicte OulesDermatology Department, Cochin Hospital, Paris, France.
Florence Brunet-PossentiDermatology Department, Bichat Claude-Bernard Hospital, Paris, France.ORCID 0000-0003-2100-2913
Anouck LamoureuxDermatology Department, Montpellier Cancer Institute, Montpellier, France.
Hugo BonnefilleDermatology Department, CHU de Nîmes, Nîmes, France.
Sorilla Mary-PreyDermatology Department, CHU de Bordeaux, Bordeaux, France.
Ana CarrasquillaDermatology Department, Leon Bérard Cancer Center, Lyon, France.
Stéphane MouretDermatology Department, CHU Grenoble Alpes, University Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Institut for Advanced Biosciences, Grenoble, France.
Nora KramkimelDermatology Department, Cochin Hospital, Paris, France.
Candice LesageDermatology Department, CHU de Montpellier, Montpellier, France.
Pierre-Emmanuel StoebnerDermatology Department, CHU de Nîmes, Nîmes, France.
Axel BartoliRadiology Department, Aix Marseille University, APHM, CERIMED, Marseille, France.
Sandrine MonestierDermatology and Skin Cancer Department, Aix Marseille University, APHM, CRCM Inserm U1068, CNRS U7258, Marseille, France.
Florian CorreardPharmacy Department, Aix Marseille University, APHM, Marseille, France.
Audrey GrosTumor Biology and Tumor Bank Department, University Hospital of Bordeaux, Bordeaux, France.
Arnaud JeansonDepartment of Early Phase Cancer Trial Center (CEPCM) "CLIP2," Aix Marseille University, APHM, Marseille, France.
L'Houcine OuafikOncobiology Department, Aix Marseille University, APHM, CNRS, INP, Inst Neurophysiopathol, Marseille, France.
Caroline Gaudy-MarquesteDermatology and Skin Cancer Department, Aix Marseille University, APHM, CRCM Inserm U1068, CNRS U7258, Marseille, France.
Pascale TomasiniDepartment of Early Phase Cancer Trial Center (CEPCM) "CLIP2," Aix Marseille University, APHM, Marseille, France.
Julie CharlesDermatology Department, CHU Grenoble Alpes, University Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Institut for Advanced Biosciences, Grenoble, France.
Mona Amini-AdleDermatology Department, Leon Bérard Cancer Center, Lyon, France.
Nausicaa MalissenDermatology and Skin Cancer Department, Aix Marseille University, APHM, CRCM Inserm U1068, CNRS U7258, Marseille, France.ORCID 0000-0001-7211-9658

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOnly a fraction of patients with metastatic melanoma derive durable benefit from approved treatments. The clinical impact of personalized medicine strategies for melanoma, apart from BRAF, NRAS, or CKIT targeting, has rarely been reported. MATERIALS AND

methodsBy means of the Group of Cutaneous Oncology of the French Society of Dermatology, we retrospectively included all patients with advanced melanoma aged 18 years and older for whom molecular testing identified one or more actionable molecular alterations and who accordingly received molecularly matched therapy. We excluded patients with only BRAF, NRAS, or CKIT alterations and patients who received molecularly matched therapy for less than 15 days.

resultsWe included 26 patients with a median follow-up of 8 months (1-54), a median age of 63 years (24-89), and a sex ratio of 2.7. These patients had been heavily pretreated, and 64% had elevated LDH levels. The disease control rate was 38%, with 4 cases of partial response (overall response rate: 15%) and 6 of stable disease for at least 6 months. The median duration of treatment was 3.1 months (0.9-13.5). Among patients with disease control, the median duration of control was 6.6 months (2.6-13.5) and 3 cases were ongoing at the end of the study. Patients with controlled disease had GNA11, MAP2K1, FYCO1-RAF1, HRAS, ATM, CCND1, MDM2/CDK4, and CDKN2A/NRAS alterations.

conclusionsHigh-throughput sequencing followed by matched targeted therapy is a promising approach for patients with advanced melanoma refractory to approved treatments.

Indexed as

MelanomaMolecular Targeted TherapyAdultAgedAged, 80 and overFemaleGTP PhosphohydrolasesHumansMaleMembrane ProteinsMiddle AgedNeoplasm MetastasisProto-Oncogene Proteins B-rafRetrospective StudiesSkin NeoplasmsYoung AdultBRAF protein, humanGTP PhosphohydrolasesMembrane ProteinsNRAS protein, humanProto-Oncogene Proteins B-rafactionable molecular alterationmelanomamolecularly matched therapyprecision medicinerefractory melanomatargeted therapy

Identifiers

PMID38761384
PMCPMC11379651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.